Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11344
Shown on this page
12
Current sort
Recently updated
Location scope
Cleveland, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cleveland, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 925–936 of 11,344 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
VEXAS, VEXAS Syndrome
Interventions
Pacritinib, Placebo
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more
Conditions
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
Interventions
Active Colchicine, Active Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
3,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Weston, Florida • Detroit, Michigan • Stony Brook, New York + 5 more
Conditions
Prion Disease
Interventions
PrP-siRNA
Drug
Lead sponsor
Broad Institute of MIT and Harvard
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Conditions
Stroke, Patent Foramen Ovale, PFO
Interventions
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Stanford, California • Thousand Oaks, California + 20 more
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
93
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more
Conditions
SCLC
Interventions
ZL-1310, Atezolizumab, Carboplatin
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Conditions
Heart Failure
Interventions
The Wise System
Device
Lead sponsor
EBR Systems, Inc.
Industry
Eligibility
22 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Mesa, Arizona • Scottsdale, Arizona • Jonesboro, Arkansas + 9 more
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AZD4045, Daratumumab, Aldesleukin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 7 more